

1642\$

Patent Attorney's Docket No. <u>032313-003</u>

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE RECEIVED

| In re Patent | Application of |) | | | JUN 2 8 | 2001 | | |
|---|---|--------|---------------------------|-----------|-----------------------|------|--|--|
| SVANBORG et al. | | | Group Art Unit: 1642 | | TECH CENTER 1600/2900 | | | |
| Application | No.: 09/555,270 |)) | Examiner: M. Wells | | | | | |
| Filed: Aug | ust 30, 2000 |) | | | | | | |
| For: TH | ERAPEUTIC AGENTS |) | | | | | | |
| | |) | | | | | | |
| | | | | | | | | |
| <u>RI</u> | ESPONSE TO RESTRICTION REQU | UIR | EMENT TRANSMIT | TAL LE | <u>TTER</u> | | | |
| Assistant C Washingto | Commissioner for Patents on, D.C. 20231 | | | | | | | |
| Sir: | | | | | | | | |
| Enclo | osed is a Response to Restriction Requir | reme | ent for the above-identi | fied pate | ent application. | | | |
| [X] | [X] A Petition for Extension of Time is also enclosed. | | | | | | | |
| [] A Terminal Disclaimer and a check for [] \$55.00 (248) [] \$110.00 (148) to cover the requisite Government fee are also enclosed. | | | | | | | | |
| [] | Also enclosed is | | | | · | | | |
| [] Small entity status is hereby claimed. | | | | | | | | |
| [] | [] Applicant(s) request continued examination under 37 C.F.R. § 1.114 and enclose the [] \$355.00 (279) [] \$710.00 (179) fee due under 37 C.F.R. § 1.17(e). | | | | | | | |
| | [] Applicant(s) previously submitte requested. | ed _ | _, on, for which co | ntinued | | | | |
| [] | Applicant(s) request suspension of ac exceed three months from the filing (§ 1.103(c). The required fee under (§ | 37 C | C.F.R. § 1.17(i) is enclo | osed. | 4 | | | |
| [] | A Request for Entry and Considerati (146/246) is also enclosed. | on (| of Submission under 37 | C.F.R. | § 1.129(a) | | | |
| ſΧΊ | No additional claim fee is required. | | | | | | | |

[] An additional claim fee is required, and is calculated as shown below:

| | No. OF CLAIMS | HIGHEST NO. OF CLAIMS PREVIOUSLY PAID FOR | EXTRA CLAIMS | RATE | ADDT'L FEE |
|---------------------------|------------------|---|-----------------|--------------------------|---------------|
| Total Claims | | MINUS = | | \times \$18.00 (103) = | |
| Independent Claims | | MINUS = | | × \$80.00 (102) = | |
| If Amendment adds mu | ltiple depend | ent claims, add \$270 | 0.00 (104) | | |
| Total Amendment Fee | | | | | |
| If small entity status is | claimed, sub | tract 50% of Total A | mendment Fo | ee | |

| [|] | A claim fee in the amount | of \$ is | enclosed. |
|---|---|---------------------------|--------------------|-----------|
| [|] | Charge \$to De | eposit Account No. | 02-4800. |

The Commissioner is hereby authorized to charge any appropriate fees under 37 C.F.R. §§ 1.16, 1.17, 1.20(d) and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 02-4800. This paper is submitted in duplicate.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

By: / W/M / C. W/M
Dawn M. Gardner

Registration No. 44,118

P.O. Box 1404 Alexandria, Virginia 22313-1404 (703) 836-6620

Date: June 25, 2001

Patent Attorney's Docket No. <u>032313-003</u>

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RESPONSE TO RESTRICTION REQUIREMENT

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

In complete response to the Restriction Requirement dated April 25, 2001, applicants offer the following remarks.

In the Restriction Requirement, the claims of the instant invention were divided into the following groups of inventions:

Group I: Claims 1-14 and 17, drawn to an agent comprising a protein complex and its first method of use.

Group II: Claims 15 and 18-19, drawn to a second method of using an agent comprising a protein complex to diagnose cancer.

Group III: Claim 16, drawn to a third method of using an agent comprising a protein complex to prepare a medicament.

Application No. <u>09/555,270</u> Attorney's Docket No. <u>032313-003</u> Page 2

Applicants hereby elect the Group I invention, directed to claims 1-7 and 14, with traverse.

This election is made with traverse. Applicants submit that the Examiner has applied the MPEP § 803 standard of restriction practice to the present application. Applicants contend that it is improper to apply the MPEP § 803 standard of restriction practice to the present application. The present application is an international application in the national stage and has been filed under 35 U.S.C. § 371. Thus, the unity of invention standard of practice should be applied to the present application.

A group of inventions is considered linked to form a single general inventive concept where there is a technical relationship among the inventions that involves at least one common or corresponding special technical feature. MPEP § 1893.03(d). If an application contains more than one invention, applicants have the right to include in a single application those inventions which are so linked as to form a single general inventive concept. Further, a group of inventions is considered linked to form a single general inventive concept where there is a technical relationship among the inventions that involves at least one common or corresponding special technical feature. The special technical feature is what defines the contribution which each claimed invention, considered as a whole, makes over the prior art. MPEP § 1893.03(d). Applicants submit that the technical feature which forms the special technical relationship among the inventions of the present application is the agent comprising a protein complex.

Application No. <u>09/555,270</u> Attorney's Docket No. <u>032313-003</u> Page 3

Several examples, which illustrate the principles of unity of invention, are found in Appendix AI of the MPEP (see the PCT Administrative Instructions, Annex B, Part 2). Examples 1 (at MPEP page AI-42) is particularly relevant to the present application.

Example 1 illustrates that unity exists between a substance and the use of the substance for some purpose. This example corresponds to the relationship between the agent of the claims of Group I and the methods of the claims of Groups I, II and III.

Accordingly, the claims of Groups I, II and II should be examined together.

Notwithstanding the above, applicants respectfully submit that, according to the MPEP § 803, a restriction between patentably distinct inventions is proper only where there is a serious burden on the Examiner to examine all the claims in a single application. This is true even when appropriate reasons exist for a restriction requirement.

In the present application, it is believed that because there is a close relationship between the subject matter of the Group I, II and II claims, there would be no serious burden on the Examiner to examine both sets of claims at this time. The claims of Group I relate to an agent comprising a protein complex, and a method of using said agent. The claims of Groups II and III also relate to methods of using said agent. Thus, the methods of Groups I, II and III are linked based upon the agent that each of the methods use. As such, there is a close relationship between the subject matter of these three sets of claims. It is respectfully believed that a search directed to the claims of Group I would include a search directed to the subject matter of the claims of Groups II and III.

In light of the above, withdrawal of the requirement for restriction between Groups I, II and III is respectfully requested. Such action is believed to be in order.

Application No.<u>09/555,270</u> Attorney's Docket No.<u>032313-003</u> Page 4

Early and favorable action in the form of a Notice of Allowance is respectfully requested.

In the event that there are any questions relating to this response or the application in general, it would be appreciated if the Examiner would contact the undersigned so that prosecution would be expedited.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

Dawn M. Gardner

Registration No. 44,118

P.O. Box 1404 Alexandria, Virginia 22313-1404 (703) 836-6620

Date: June 25, 2001